Metabolic syndrome and cardiovascular disease after haematopoietic cell transplantation (HCT) in adults: an EBMT cross-sectional non-interventional study. by Greenfield, D M et al.
ARTICLE OPEN
Metabolic syndrome and cardiovascular disease after
haematopoietic cell transplantation (HCT) in adults: an EBMT
cross-sectional non-interventional study
D. M. Greenfield 1✉, N. Salooja 2, C. Peczynski 3, S. van der Werf4, H. Schoemans 5, K. Hill 6, A. Cortelezzi7,
M. Lupo-Stangellini 8, Z. N. Özkurt9, M. Arat10, B. Metzner11, P. Turlure12, A. Rovo 13, G. Socié14, M. Mohty 15, A. Nagler 16,
N. Kröger 17, P. Dreger 18, M. Labopin 3, T. S. Han 19, A. Tichelli20, R. Duarte21, G. Basak22 and J. A. Snowden 1
© The Author(s) 2021
Metabolic syndrome (MetS) is associated with cardiovascular disease in the general population and is also a potential cardiovascular
risk factor in survivors of haematopoietic cell transplantation (HCT). We report an EBMT cross-sectional, multi-centre, non-
interventional study of 453 adult HCT patients surviving a minimum of 2 years post-transplant attending routine follow-up HCT
and/or late effects clinics in 9 centres. The overall prevalence of MetS was 37.5% rising to 53% in patients >50 years of age at follow-
up. There were no differences in rates of MetS between autologous and allogeneic HCT survivors, nor any association with graft-
versus-host disease (GvHD) or current immunosuppressant therapy. Notably, there was a significantly higher occurrence of
cardiovascular events (CVE, defined as cerebrovascular accident, coronary heart disease or peripheral vascular disease) in those with
MetS than in those without MetS (26.7% versus 9%, p < 0.001, OR 3.69, 95% CI 2.09–6.54, p < 0.001), and, as expected, MetS and CVE
were age-related. Unexpectedly, CVE were associated with occurrence of second malignancy. Screening for and management of
MetS should be integrated within routine HCT long-term follow-up care for both allogeneic and autologous HCT survivors. Further
research is warranted, including randomised controlled trials of interventional strategies and mechanistic studies of cardiovascular
risk in HCT survivors.
Bone Marrow Transplantation; https://doi.org/10.1038/s41409-021-01414-7
INTRODUCTION
Metabolic syndrome (MetS) is typically defined as a clustering of
five factors including (1) hyperglycaemia (2) hypertriglyceridae-
mia; (3) low high-density lipoprotein (HDL) cholesterol; (4)
hypertension; (5) obesity (measured by high waist circumference)
[1, 2]. The prevalence is estimated to be about one quarter of the
world population [3]. This cluster of interrelated risk factors has
been shown to increase the risk of cardiovascular (CV) disease,
diabetes mellitus (DM) and all-cause mortality [2, 4]. Various
definitions of MetS have been proposed but currently, an
international harmonised definition given by the International
Diabetes Federation (IDF) [1] defines MetS as 3 out of 5 risk factors,
as follows: abdominal obesity, measured by waist circumference
(using population and country-specific definitions): triglycerides
(TG) ≥1.7 mmol/l, or drug treatment for elevated levels; high-
density lipid–cholesterol with gender specific cut-offs (men <1.0
mmol/l, women <1.3 mmol/l or drug treatment for reduced levels);
blood pressure ≥130/≥85mmHg or drug treatment for hyperten-
sion; fasting glucose ≥5.6 mmol/L or drug treatment for DM.
Another commonly used definition is the NCEP ATP III definition
[4]. For this, MetS is present if three or more of the following five
criteria are met (using imperial measures): waist circumference
over 40 inches (men) or 35 inches (women), blood pressure over
130/85mmHg, fasting TG level over 150 mg/dl, fasting HDL
cholesterol level less than 40mg/dl (men) or 50mg/dl (women)
and fasting blood sugar over 100mg/dl.
One significant practical issue is the variable definition of MetS
used across published studies and in clinical practice, generally
and in relation to haematopoietic cell transplantation (HCT). Using
a population-based study of randomly selected participants,
Mancia et al. [5] have previously compared the predictive value
of the various definitions of MetS and found this was significantly
greater when using the criteria of the American Heart Association
[6] and the IDF [1] definitions compared with the that of the
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National Cholesterol Education Programme Adult Treatment Panel
III (NCEP ATPIII) [4] definition. In their literature review, O’Neill and
O’Driscoll [7] tabulated the rates of MetS by the two definitions
(NCEP ATPIII and IDF) with consistently higher rates using the IDF
definition across a number of studies. The IDF method is now
proposed to be superior at diagnosing MetS compared with that
of the NCEP ATPIII [7].
Compared with the general population, the prevalence of MetS
is increased in long-term cancer survivors in both adult [5–8] and
paediatric survivors [9–11]. Furthermore, there is evidence of
increased morbidity and mortality from CV disease in populations
of general cancer patients [12, 13]. Some studies have included
HCT recipients, but they have been mixed in their patient
populations, variable in their definition of MetS and other
endpoints, and in their conclusions. With respect to an increased
risk of CV disease after HCT, retrospective studies from the
European Society for Blood and Marrow Transplantation (EBMT)
found 3.6% of long-term survivors of allogeneic HCT had a
cardiovascular event (CVE) in at least one arterial territory; the
cumulative incidence of a first CVE 15 years after HCT was 6%
which increased to 7.5% in allograft survivors compared with 2.3%
post autologous HCT [12, 13]. Another large retrospective study in
a North American population reported 10-year cumulative
incidences of ischaemic heart disease, cardiomyopathy, stroke
and all-cause CV death of 3.8%, 6%, 3.5% and 3.7% respectively
[14], with a similar prevalence of CV disease in autologous and
allogeneic HCT.
A number of individual mechanistic factors potentially con-
tribute to the increased risk of CV disease following HCT including
pre-existing risk factors, pre-transplant treatment, the transplant
itself (including graft-versus-host disease, GvHD) and post-
transplant treatment and the contribution of immune dysfunction
and endocrinopathies [14–25].
Although the precise relationship between HCT, MetS and CV
disease needs further clarification, screening for MetS following
HCT has been incorporated into international guidelines for long-
term follow up of HCT patients [26–28]. Even so, the incidence and
impact of MetS as a risk factor for CV disease following various
types and intensities of HCT remains unclear.
We therefore conducted a large cross-sectional, multi-centric
service evaluation of HCT survivors in EBMT centres working in
accordance with international screening guidelines for long-term
follow up of HCT survivors [26]. The primary objective was to
establish the prevalence of MetS following various types of HCT in
consecutive patients returning for routine follow-up over a 1-year
period at participating EBMT centres. Secondary objectives were
to evaluate the association of MetS with a range of patient and
HCT-related variables and discern the discriminatory ability of
both MetS definitions (IDF and ATPIII) in the HCT survivor
population.
SUBJECTS AND METHODS
This was a multi-centre, cross-sectional, non-interventional observational
study. The study was approved and conducted according to EBMT
procedures with data collection and further evaluation coordinated
centrally by the EBMT Leiden Data Office, The Netherlands, with statistical
analysis performed by the EBMT Office Paris, France. All patients provided
written consent at transplant for the collection, transmission and analysis
of anonymised data within EBMT.
Inclusion criteria
Patients transplanted as adults (aged ≥18 years) were eligible for inclusion
if they had received allogeneic (myeloablative or reduced intensity) or
autologous HCT with curative intent. Patients had to be a minimum of 2
years post HCT and be attending a routine follow-up appointment at one
of nine participating EBMT centres. The patients treated with non-curative
intent (e.g. patients with myeloma or low grade non-Hodgkin lymphoma
(NHL) treated with autologous HCT) were not eligible.
Data collection
Transplantation-related data for each patient was extracted from the EBMT
registry and included age, gender, ethnicity and details regarding
allogeneic or autologous HCT with dates, type of conditioning regimen:
myeloablative +/− total body irradiation (TBI)/reduced intensity con-
ditioning (RIC), acute GvHD (aGvHD) grade, chronic GvHD (cGvHD) grade,
Eastern Cooperative Oncology Group (ECOG) performance status, and
details of any second or newly occurring malignancy (including skin
cancers) with date of diagnosis. Histological confirmation was not routinely
collected.
In advance of the study, the EBMT Leiden Data Office emailed all EBMT
transplant centres seeking interested centres to participate. Nine centres
agreed to participate in the study and went on to enter patients into the
study. No information was gathered regarding the socioeconomic diversity
or follow-up schedule of the participating centres. Participating centres
also completed study-specific EBMT ‘MED C’ forms for each patient. MED C
routine clinical recording included parameters for MetS (such as diabetes,
hypertension, dyslipidaemia, waist circumference). In addition, the follow-
ing were all collected; performance status (ECOG); height (accepting
baseline/previously measured height) and weight; evidence of previous
CVE based on the categories as defined by Tichelli et al. [29]; family history
of premature CV disease (parents <60 years), existing diagnosis of Type 2
DM pre-HCT, menstrual history in women, previous and current smoking
and calculation of pack-years smoked (number of packs of cigarettes
smoked per day multiplied by the number of years the person has
smoked), previous and current alcohol use (using UK guidelines to
calculate the number of units per week). Previous or current drug history
was also recorded on the MED C form including use of: immuno-
suppressive therapy, particularly use of cyclosporine and tacrolimus,
sirolimus; corticosteroid dosage including previous or current prednisolone
equivalent doses; anti-lipid drugs; anti-hypertensives (including ACE
inhibitors, beta-blockers, diuretics used for hypertension not fluid balance);
diabetic medications (including insulin and metformin); hormone replace-
ments (including contraceptive use in women). Data were coded under
unique patient numbers and all centres submitted completed study data
for integration within the EBMT Registry to a central data office (the EBMT
Leiden Data Office) by established reporting routes. Definitions of the
ATPIII and IDF criteria were as published [1, 4, 5].
Routine clinical tests
Routine clinical tests. including TGs, HDL and LDL cholesterol, plasma
glucose, total testosterone or oestradiol and gonadotrophins, sex hormone
binding globulin, thyroid-stimulating hormone and T4, were performed for
each patient at the follow-up appointment and results recorded on the
MED C form as within range, elevated or lower than local reference ranges.
Patients were reviewed in routine follow-up clinics and blood taken under
normal conditions according to local clinic arrangements. Fasting blood
results were not always available in which case non-fasting plasma glucose
cut-offs were used according to the American Diabetes Association
guidance [30].
Statistical analysis
Statistical analyses were performed using R3.2.3. The prevalence of MetS
was estimated in the population by age decade and follow-up duration
from HCT using two different definitions (IDF and ATP III) [1, 2]. Univariate
comparison of patients and HCT characteristics between the two groups
(MetS vs no MetS) was performed using the non-parametric Mann–Witney
U test for continuous variables and Chi-square test or Fisher’s exact test for
categorical variables. All tests were two-sided. Multivariate logistic
regression analysis was performed to adjust for confounding factors that
may have an impact on the association between MetS and previous CVE.
Variables with a p value <0.2 in univariate analysis were included. The
results are expressed as odds ratio (OR) with a 95% confidence interval
(95% CI). The association of the two MetS definitions with the presence/
absence of previous CVE was analysed using Receiver Operating




Four hundred and fifty-three patients (258 men and 195 women)
were evaluated (366, 80.8% allogeneic and 87, 19.2%















autologous HCT). Table 1 gives the population demographics in
terms of age, gender, ethnicity, primary diagnosis, conditioning type,
ECOG status at time of evaluation (i.e. baseline), and history of second
malignancy. Two patients labelled as having plasma cell disorders
were entered inadvertently by two centres and were identified after
data cleansing. Their results were not outlying and thus, for pragmatic
reasons, their data remained in the analysed dataset.
Relationship of MetS definition with CV events
To establish which definition of MetS is appropriate for use related
to HCT survivors, we investigated the presence of criteria in a sub-
cohort already identified as having a CVE [29] using ROC analysis
to compare the AUC between the ability of ATPIII and IDF
metabolic criteria for an “ever” CVE using DeLong’s test. Neither
MetS definition was significantly associated with the occurrence of
a previous CVE (p= 0.65).
Prevalence of MetS
We present the prevalence of MetS using both definitions and
then present further results related to the IDF definition only, since
we found no superiority (using ROC analysis) of one definition
over another and the given published preference for using the IDF
definition [7].
Using both the harmonised (IDF) definition of MetS (at least 3/5
factors), and the ATPIII definition, the prevalence of MetS was
37.5% and 43.5% respectively. The prevalence rate for allogeneic
HCT patients was 36.4% using IDF and 42.9% using ATPIII
definitions, and for autologous HCT patients was 42.3% and
46.2% for each definition, respectively. Table 2 gives the
prevalence rates of MetS by each definition and for each of the
MetS risk factors for the whole cohort, and by transplant type.
There was a significant difference in prevalence of MetS by age
at diagnosis, age at HCT and age at follow-up (all p < 0.001 with
increasing age) using both definitions. Logistic regression showed
there was an influence of increasing age at follow up in the
prevalence of MetS using the IDF definition (odds ratio (OR) 8.7,
95% CI 4.2,18.1) for the > 50 years age group compared with those
aged 18–29 years. Statistically significant differences in BMI were
observed between patients with and without MetS (28.2 [IQR
25.6–31] vs 23.3 [IQR 21.3–25.9], respectively, p < 0.001; results not
shown).
Relationship of MetS with history of CV disease
Notably, irrespective of the type of HCT, there was a significantly
higher frequency of history of CVE (cerebrovascular accident,
coronary heart disease and peripheral vascular disease) in those
with MetS than in those without (26.7.vs 9.0%, p < 0.0001).
Eighteen out of 210 (8.6%) allogeneic HCT patients without MetS
reported at least one CVE compared with 30/120 (25%) of patients
with MetS (p < 0.0001). Similarly, in autologous HCT patients, 4/45
(8.9%) without MetS reported a CVE as compared to 9/33 (27.3%)
with MetS (p= 0.03). Logistic regression analysis showed an
influence of increasing age at transplant with increasing
prevalence of CVE (OR 3.49, 95% CI 1.54, 7.89, p= 0.003) for the
over 50 s compared with those aged 18–29 years at transplant
(results not shown).
Relationship of MetS with pre-transplant risk factors for CV
disease
There was no relationship between prevalence of MetS (following
HCT) and reported family history of CV disease, or with reported
alcohol use.
Smoking status was reported as current for 44 patients, 155
reported being previous smokers, and 205 as never smokers. For
patients with MetS, the OR for smoking >10 pack years compared
with smoking ≤10 pack years or less was 2.7 (95% CI 1.68, 4.33, p <
0.001).
Table 1. Patient demographics.
Variable Overall Allogeneic Autologous

































Male 258 (57.0) 212 (57.9) 46 (52.9)
Female 195 (43.0) 154 (42.1) 41 (47.1)
Diagnosis, n (%)
Acute leukaemia 172 (38.0) 162 (44.3) 10 (11.5)
Chronic leukaemia 57 (12.6) 57 (15.6) 0 (0.0)
Lymphoma 125 (27.6) 51 (13.9) 74 (85.1)
Plasma cell
disorders
22 (4.9) 20 (5.5) 2 (2.3)
Solid tumours 1 (0.2) 0 (0.0) 1 (1.2)
Myelodysplastic/
Myeloproliferative
58 (12.8) 58 (15.8) 0 (0.0)
Bone marrow
failure
17 (3.8) 17 (4.6) 0 (0.0)




444 (98.7) 358 (98.6) 86 (98.9)
South and South-
East Asian




1 (0.2) 1 (0.3) 0 (0.0)
African Caribbean 1 (0.2) 1 (0.3) 0 (0.0)
Missing 3 3 0
ECOG at time of evaluation, n (%)
0 333 (76.2) 267 (76.1) 66 (76.7)
1 90 (20.6) 74 (21.1) 16 (18.6)
2 11 (2.5) 8 (2.3) 3 (3.5)
3 2 (0.5) 1 (0.3) 1 (1.2)
4 1 (0.2) 1 (0.3) 0 (0.0)
Missing 16 15 1





Second malignancy (any kind), n (%)
No 392 (89.7) 316 (89.0) 76 (92.7)
Yes 45 (10.3) 39 (11.0) 6 (7.3)
Missing 16 11 5
IQR interquartile range, MAC myeloablative conditioning, RIC reduced
intensity conditioning, TBI total body irradiation.
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Of 45 patients with pre-existing type II diabetes, 35 had MetS
and 10 did not.
Relationship of MetS with HCT intensity
For patients who received an allogeneic HCT, no relationship
between prevalence of MetS and conditioning intensity was
observed between the following groups: those who received
myeloablative conditioning (n= 158) and those who received RIC
(n= 174); those who received TBI (n= 129) and those who did not
(n= 235); those who had myeloablative conditioning with
chemotherapy only (n= 73) and those who had myeloablative
conditioning with TBI (n= 85). The median age at treatment for
those who received myeloablative conditioning was 37.7 years
(IQR 27.6–46.7) compared with 51.1 for those who received RIC
(IQR 42.1–57.5). Similarly the median age at treatment for those
who received TBI was 38.1 years (IQR 29.5–46.5) compared with
46.1 years who did not receive TBI (IQR 33.1–55.1).
Relationship of MetS with medication use
No association was evident between prevalence of MetS and
current or previous use of immunosuppressant therapy (p= 0.23),
significant corticosteroid treatment use (e.g. prednisolone,
methylprednisolone, dexamethasone) for more than 28 days post
HCT (p= 0.6) or hormone replacement use (i.e. oral contraceptive
pill or hormone replacement in women, or testosterone replace-
ment in men) (p= 0.87; results not shown).
Relationship of MetS with GvHD
For patients who had received allogeneic HCT, no relationship was
observed between prevalence of MetS and confirmation
(answered as yes/no) of grade II to IV aGvHD (p= 0.82) or cGvHD
(p= 0.66; results not shown).
Second or newly occurring malignancies
Forty-five of 392 patients were reported to have a second or newly
occurring malignancy recorded post HCT (answered as yes/no,
without specification of tumour type). There was no observed
difference between those with and without a second malignancy
and the prevalence of MetS (p= 0.10). Unexpectedly, univariate
logistic regression analysis showed that a CVE with occurrence of a
second malignancy carried an OR of 2.83 (95% CI 1.38, 5.81 p=
0.005).
DISCUSSION
This cross-sectional, non-interventional survey represents the
largest multi-centre ‘real life’ evaluation of MetS in HCT survivors
and confirms a high prevalence of MetS following both allogeneic
and autologous HCT; 37.5% overall rising to 52.8% in those aged
over 50 years at follow-up. The data support MetS being an age-
related late effect of HCT strongly associated with CVE.
This prevalence concurs with previous smaller single centre
studies in adult HCT practice [31, 32] irrespective of type of HCT.
Based on a previous study [18], a higher prevalence of MetS and
CVE in allogeneic HCT patients compared with autologous HCT
might have been anticipated given the generally more intensive
nature of allogeneic HCT treatment, with a higher rate of
subsequent complications such as GvHD and its treatments,
which include corticosteroids, calcineurin inhibitors and other
drugs with CV risk. However, our study did not support the
prevalence of MetS being significantly related to these factors.
Although there was an effect of increasing prevalence with
increasing age demonstrated in the multivariate analysis (i.e. lower
in the allogeneic HCT cohort) and/or patient selection (i.e. lower
co-morbidities in the allogeneic HCT group), MetS and CV risk
similarly affected both autologous and allogeneic HCT survivors.
Therefore, consideration of MetS should extend beyond the
‘curative intent’ groups (NHL and HL) included in this study to
other patients undergoing autologous HCT.
In our study ATP III and IDF definitions were not significantly
different or in their association with a CVE, consistent with other
reports in the general population. IDF defines MetS features below
treatment thresholds, therefore allows earlier identification of ‘at-
risk’ patients [33]. We chose the IDF definition because in terms of
performance using the ROC analysis, not one definition was
superior to the other meaning we defaulted to the IDF, the
international definition of choice [7].
The association between the occurrence of second malignancy
and CV disease is notable. Although we did not find an association
between MetS and cancer as such, MetS has been associated with
many cancers including breast, pancreatic, colon and liver, and
each individual risk factor for MetS has also an association with













No 255 (62.5) 210 (63.6) 45 (57.7)
Yes 153 (37.5) 120 (36.4) 33 (42.3)






No 226 (56.5) 184 (57.1) 42 (53.9)
Yes 174 (43.5) 138 (42.9) 36 (46.2)





Normal 149 (33.0) 123 (33.6) 26 (30.2)
Elevated 303 (67.0) 243 (66.4) 60 (69.8)




Normal 186 (48.6) 140 (47.1) 46 (53.5)
Elevated 197 (51.4) 157 (52.9) 40 (46.5)




Normal 273 (63.8) 220 (63.0) 53 (67.1)
Low 155 (36.2) 129 (37.0) 26 (32.9)




Normal 176 (39.0) 147 (40.2) 29 (34.1)
Elevated 275 (61.0) 219 (59.8) 56 (65.9)




Normal 371 (88.8) 301 (89.6) 70 (85.4)
Elevated 47 (11.2) 35 (10.4) 12 (14.6)
Missing 35 30 5
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cancer [7]. Alternatively, time after transplant may be a
confounding variable, reflecting an increase in both malignancies
and in CV disease in the years after HCT. Future studies to
elucidate the association of MetS and second malignancy are
required, including specific tumour types, as this information may
be useful for long-term lifestyle advice post-HCT.
Our study is limited in a number of respects, particularly by its
cross-sectional nature. We were not able to establish the time of
onset of MetS in relation to either a pre-existing prevalence or the
treatment/transplant received. It is likely with a longer follow-up
time and longitudinal sequential evaluation, the greater the
probability of CVE. Caution is required in comparisons between
allogeneic and autologous HCT because of different indications
and also regarding risk of second malignancy since all cancer
types, including skin cancers were included in the analysis. There
were also procedural limitations, including the non-interventional
evaluation of patients in ‘routine’ clinics. As such, we used the
non-fasting cut-offs for blood glucose defined by the American
Diabetes Association guidance [30], which may have under-
estimated levels of diabetes. Furthermore, registry data might not
have been fully complete (for example accuracy of recording all
secondary malignancies) and potentially affected by recall bias.
There was also a possibility of recruitment bias linked to a
motivated population attending follow-up/late effects clinic. In
addition, two patients labelled as having plasma cell disorders
were entered inadvertently from two centres and were identified
after data cleansing. Their results were not outlying and thus, for
pragmatic reasons, their data remained in the analysed dataset.
A further limitation to this study was a limitation in diversity of
ethnic groups. Although differences in MetS by race and ethnicity
are recognised, much of the research on management and
prevention of MetS has focused almost entirely on European-
derived populations and also in low and middle income countries
[34]. Further studies should elucidate these aspects and implica-
tions for practice. Finally, the study lacked a control population.
Despite the limitations, this is the largest study of MetS in the
setting of HCT and has implications for clinical and research
practice. Although variably defined, MetS is a basis for on-going
management of CV risk with lifestyle modification and pharma-
cological intervention. Screening and management of MetS and
CV risk should be integrated within models of routine long-term
follow-up care in both allogeneic and autologous HCT according
to international guidelines and recommendations [28, 35].
Early intervention of reversible features of MetS with lifestyle
and medical management may reduce CVE, but this needs to be
tested prospectively, and ultimately in randomised controlled
trials in HCT patients. Scoring systems for CV disease, like
Framingham [36] and QRISK [37], used commonly in the general
population, require validation in the HCT population, and
‘bespoke’ systems need to be developed.
In conclusion, our study has confirmed a high prevalence of
MetS in both allogeneic and autologous HCT survivors, and a
strong association between MetS and CVE. Further clinical and
scientific research is warranted into patient, donor, transplant
technique, graft source, pre-treatment, immunosuppression or
other potential influencing factors, as well as mechanisms. In the
meantime, screening should be incorporated in long-term follow
up of all HCT patients.
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